Professor Shuajp Kraja is the Albanian first inventor holding the European patent for the anti-cancer vaccine Bi. Regarded as an invention in the field of medicine, the issuance of this patent by the European Patent Organization (EPO), paves the way for production’s authorized procedures by the European Union.
As part of the pilot study with volunteer patients, several dozen cases were treated and cured with anticancer vaccine BI for a long time over the years. It provides full treatment of various forms of cancers, without recurrence.
Bi vaccine constitutes a treatment much more suited that competes and will replace the heavy “artillery” of chemotherapy and radiotherapy as an intelligent injection (hyper immune T- lymphocytes with new selective information), which will be able to recognize and selectively kill malignant cells among trillions of body cells (normal and malignant), without harming the healthy cells of the body.
Bi vaccine is applied for treating various forms of cancer and also for immunization against cancer occurrence in healthy people, but likely to develop cancer.
The patent for this invention is known in many countries and international institutions like the European Office, Germany, Switzerland, France, UK, Ireland, Albania, Kosovo and Croatia.
Professor Kraja has also obtained a second patent for the drug “Shukrain 55” on the European level, also registered at the Patent and Trademark Registration, this time in Germany.
The medicine has a wide spectrum and is also proven effective against pathogenic viruses hazardous to human health, such as HIV AIDS, viral hepatitis, influenza, preventing its outbreak.
In the spring of 2015, recognition of this drug as medicinal patented innovation was confirmed and was given the right to industrial production.
Introduction of this drug in the international market is regarded as a necessity, based on its curative and healing effects against a variety of viral bacterial diseases.
It is considered as a very necessary patented innovation for global pharmaceuticals, particularly where WHO raises alarm about antibiotic resistance and their protracted absence in the market.
Prof. Shuajp Kraja is born in the city of Shkodra in 1936. Specialized in molecular biology, he has a rich academic and scientific career, beyond the Albanian borders.
http://skymastergroup.com/en/media-marketing/article-drshuajp-kraja-international-innovation
As part of the pilot study with volunteer patients, several dozen cases were treated and cured with anticancer vaccine BI for a long time over the years. It provides full treatment of various forms of cancers, without recurrence.
Bi vaccine constitutes a treatment much more suited that competes and will replace the heavy “artillery” of chemotherapy and radiotherapy as an intelligent injection (hyper immune T- lymphocytes with new selective information), which will be able to recognize and selectively kill malignant cells among trillions of body cells (normal and malignant), without harming the healthy cells of the body.
Bi vaccine is applied for treating various forms of cancer and also for immunization against cancer occurrence in healthy people, but likely to develop cancer.
The patent for this invention is known in many countries and international institutions like the European Office, Germany, Switzerland, France, UK, Ireland, Albania, Kosovo and Croatia.
In the spring of 2015, recognition of this drug as medicinal patented innovation was confirmed and was given the right to industrial production.
Introduction of this drug in the international market is regarded as a necessity, based on its curative and healing effects against a variety of viral bacterial diseases.
Article of Dr.Shuajp Kraja on International Innovation
http://skymastergroup.com/sites/default/files/Article%20of%20Dr.Shuajp%20Kraja%20on%20International%20Innovation.pdfhttp://skymastergroup.com/en/media-marketing/article-drshuajp-kraja-international-innovation
